REPL Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of 49.9%. Replimune Group, Inc.'s return on equity of -92.13% beat CorMedix, Inc.'s return on equity of 95.25%.

Replimune Group, Inc. has a consensus price target of $12.86, signalling upside risk potential of 65.9%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 93.2%. Given that CorMedix, Inc. has higher upside potential than Replimune Group, Inc., analysts believe CorMedix, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.727, which suggesting that the stock is 27.342% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Replimune Group, Inc.'s net income of -$70.9M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 2.59x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of -1144.46%. Replimune Group, Inc.'s return on equity of -92.13% beat Ocugen, Inc.'s return on equity of -345.08%.

Replimune Group, Inc. has a consensus price target of $12.86, signalling upside risk potential of 65.9%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 576.69%. Given that Ocugen, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Ocugen, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.727, which suggesting that the stock is 27.342% less volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 3.493, suggesting its more volatile than the S&P 500 by 249.3%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Replimune Group, Inc.'s net income of -$70.9M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 73.00x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of -45.06%. Replimune Group, Inc.'s return on equity of -92.13% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Replimune Group, Inc. has a consensus price target of $12.86, signalling upside risk potential of 65.9%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $21.43 which suggests that it could grow by 15.86%. Given that Replimune Group, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Replimune Group, Inc. is more attractive than Sarepta Therapeutics, Inc..

Replimune Group, Inc. has a beta of 0.727, which suggesting that the stock is 27.342% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.731%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Replimune Group, Inc.'s net income of -$70.9M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 0.79x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -- compared to Replimune Group, Inc.'s net margin of -876.34%. Replimune Group, Inc.'s return on equity of -92.13% beat Verastem, Inc.'s return on equity of -1773.4%.

Replimune Group, Inc. has a consensus price target of $12.86, signalling upside risk potential of 65.9%. On the other hand Verastem, Inc. has an analysts' consensus of $16.63 which suggests that it could grow by 149.25%. Given that Verastem, Inc. has higher upside potential than Replimune Group, Inc., analysts believe Verastem, Inc. is more attractive than Replimune Group, Inc..

Replimune Group, Inc. has a beta of 0.727, which suggesting that the stock is 27.342% less volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.56%.

Replimune Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Replimune Group, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Replimune Group, Inc. quarterly revenues are --, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Replimune Group, Inc.'s net income of -$70.9M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Replimune Group, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Replimune Group, Inc. is -- versus 31.17x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.